{"id":"NCT04666259","sponsor":"Novartis Pharmaceuticals","briefTitle":"Asciminib in Monotherapy for Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With and Without T315I Mutation","officialTitle":"An Open Label, Multi-center Phase IIIb Study of Asciminib (ABL001) Monotherapy in Previously Treated Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With and Without T315I Mutation","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2021-05-25","primaryCompletion":"2023-06-20","completion":"2024-06-26","firstPosted":"2020-12-14","resultsPosted":"2024-07-12","lastUpdate":"2025-07-04"},"enrollment":56,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Myelogenous Leukemia - Chronic Phase"],"interventions":[{"type":"DRUG","name":"ABL001","otherNames":[]}],"arms":[{"label":"Cohort A","type":"EXPERIMENTAL"},{"label":"Cohort B","type":"EXPERIMENTAL"},{"label":"Cohort C","type":"EXPERIMENTAL"}],"summary":"This study was a multicenter Phase IIIb open-label, three-cohort study of asciminib in patients with CML-CP without T315I mutation who have had at least 2 prior TKIs and CML-CP harboring the T315I mutation with at least 1 prior TKI","primaryOutcome":{"measure":"Number of Participants With Adverse Events and Serious Adverse Events for Cohorts A and B up to 24 Weeks","timeFrame":"Baseline to up to 24 Weeks","effectByArm":[{"arm":"Cohort A","deltaMin":23,"sd":null},{"arm":"Cohort B","deltaMin":26,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":26,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":25},"commonTop":["Fatigue","Arthralgia","Headache","Nausea","Diarrhoea"]}}